News

Video

Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial

Author(s):

Misako Nagasaka, MD, PhD

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

Related Videos
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
Sandip P. Patel, MD
Alissa J. Cooper, MD
Related Content
Ewa Kalinka, MD, PhD, of the Instytut Centrum Zdrowia Matki Polki-Klinika Onkologil
September 13th 2024

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Glenwood Goss, MB, BCh, FCPSA, FRCPC
September 13th 2024

Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Lung cancer - stock.adobe.com
September 12th 2024

Plinabulin Plus Docetaxel Boosts OS in Pretreated EGFR Wild-Type NSCLC

Danny Nguyen, MD
September 11th 2024

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC